Nitric oxide and endothelin after lipid apheresis - a pilot study

Area of Science:

• Cardiovascular Research
• Endothelial Function
• Lipid Metabolism

Background:

• Familial hypercholesterolemia (FH) causes premature atherosclerosis due to impaired vascular endothelial function.
• The mechanisms behind endothelial function improvement after lipid apheresis, specifically concerning nitric oxide (NO) production and vasoconstrictor turnover (e.g., endothelin-1 [ET-1]), remain unclear.

Purpose of the Study:

• To investigate the impact of LDL apheresis on endothelial function markers in patients with severe FH.
• To explore the roles of nitric oxide (NO) synthesis pathways and endothelin-1 (ET-1) in endothelial function changes post-apheresis.

Main Methods:

• Recruited patients with severe FH undergoing regular LDL apheresis.
• Measured serum lipids, L-arginine (L-Arg), L-hydroxyarginine (NHA), L-citrulline, big endothelin (Big-ET), and endothelin-1 (ET-1) before and after different apheresis systems (DALI, HELP, TheraSorb).

Main Results:

• Apheresis significantly reduced total cholesterol (TC), LDL-C, and triglycerides (TG).
• L-arginine (L-Arg) levels transiently decreased post-apheresis, returning to baseline within 2 hours.
• Endothelin-1 (ET-1) and Big-ET increased after HELP apheresis but transiently decreased with DALI and Therasorb, suggesting system-dependent effects.

Conclusions:

• Endothelial function improvement after apheresis is multifactorial.
• Further research is needed to fully understand the interplay between endothelial dysfunction, NO synthesis, and vasoactive mediators like ET-1 in FH patients treated with apheresis.